Hepatitis B: Diagnosis, natural history, treatment and prevention;Hepatitis B virusinfektion: Diagnose, klinische folgen, therapie und prophylaxe

Praxis

Volumn 91, Issue 8, 2002, Pages 307-319

  Reichen, J ^a,b   Grob, P J ^a  

^a Inst fur Klinische Pharmakologie   (Switzerland)

^b Inst fur Klinische Pharmakologie   (Germany)

Author keywords

Interferon; Lamivudin; Morbidity; Mortality; Vaccination

Indexed keywords

INTERFERON; LAMIVUDINE;

CHRONIC DISEASE; HEPATITIS B; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; PROPHYLAXIS; REVIEW; SERODIAGNOSIS; SEXUAL BEHAVIOR; SWITZERLAND; VACCINATION;

EID: 0037138801     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.91.8.307     Document Type: Review

References (74)

1. Lok, A. S., Heathcote, E. J., and Hoofnagle, J. H.: Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology, 120: 1828-1853, 2001.
2. Bart, P.A., Jacquier, P., Zuber, P. L. et al.: Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. Liver, 1996 Apr;16: 110-116, 1996.
3. Opravil, M., Hunziker, R., Luthy, R. et al.: Chronische Hepatitis B und C bei HIV-infizierten Patienten. Dtsch.Med Wochenschr., 123: 753-760, 12-6-1998.
4. Hoofnagle, J. H., Dusheiko, G. M., Seeff, L. B. et al.: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann.Intern.Med., 94: 744-748, 1981.
5. Carman, W. F., Jacyna, M. R., Hadziyannis, S. et al.: Mutation preventing formation of hepatitis B e antigen in patients with chronic B infection. Lancet, ii: 588-590, 1989.
6. Brunetto, M. R., Stemler, M., Bonino, F. et al.: A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J.Hepatol., 10: 258-261, 1990.
7. Center for Disease Control: General recommendations on immunisation. MMWR, 43: 1-6-1994.
8. Dermicheli, V., and Jefferson, T. O.: Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy. Journal of Public Health Medicine, 14: 367-375, 1992.
9. Van Damme, P., Thormans, G., Kane, M. et al.: A European risk model for hepatitis B among health care workers. European Journal of Public Health, 5: 245-252, 1995.
10. Tassopoulos, N. C., Papaevangelou, G. J., Sjoegren, M. H. et al.: Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterotogy, 92: 1844-1850, 1987.
11. Teo, E. K., Ostapowicz, G., Hussain, M. et al.: Hepatitis B infection in patients with acute liver failure in the United States. Hepatology, 33: 972-976, 2001.
12. Yotsuyanagi, H., Yasuda, K., Iino, S. et al.: Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology, 27: 1377-1382, 1998.
13. Bréchot, C., Thiers, V., Kremsdorf, D. et al.: Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology, 34: 194-203, 2001.
14. Davis, G. L., Hoofnagle, J. H., and Waggoner, J. G.: Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology, 86: 230-235, 1984.
15. Dragosics, B., Ferenci, P., Hitchman, E. et al.: Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: A clinical and histologic evaluation of 242 cases. Hepatology, 7: 302-306, 1987.
16. De Franchis, R., Meucci, G., Vecchi, M. et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann.Intern.Med., 118: 191-194, 1993.
17. Villeneuve, J. P., Desrochers, M., Infante-Rivard, C. et al.: A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology, 106: 1000-1005, 1994.
18. Villa, E., Barchi, T., Grisendi, A. et al.: Susceptibility of chronic symptomless HBsAg carriers to ethanol- induced hepatic damage. Lancet, ii: 1243-1244, 1982.
19. Grob, P., Jilg, W., Gerken, G. et al.: Serological Pattern "Anti-HBc Alone": Report on a Workshop. J.Med.Virol., 62: 450-455, 2000.
20. Weissberg, J. I., Andres, L. L., Smith, C. I. et al.: Survival in chronic hepatitis B. Ann.Intern.Med., 101: 613-616, 1984.
21. Di Marco, V., Lo Iacono, O., Commà, C. et al.: The long-term course of chronic hepatitis B. Hepatology, 30: 257-264, 1999.
22. De Jongh, F, E., Janssen, H. L. A., De Man, R. A. et al.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology, 103: 1630-1635, 1992.
23. Realdi, G., Fattovich, G., Hadziyannis, S. et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. J.Hepatol., 21: 656-666, 1994.
24. Tine, F., Liberati, A., Craxi, A. et al.: Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J.Hepatol., 18: 154-162, 1993.
25. Wong, D. K. H., Cheung, A. M., O'Rourke, K. et al.: Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis. A meta-analysis. Ann.Intern.Med., 119: 312-323, 1993.
26. Lau, D. T., Everhart, J., Kleiner, D. E. et al.: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology, 113: 1660-1667, 1997.
27. Niederau, C., Heintges, T., Lange, S. et al.: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N.Engl.J.Med., 334: 1422-1427, 1996.
28. Commà, C., Giunta, M., Andreone, P. et al.: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J.Hepatol., 34: 593-602, 2001.
29. Dusheiko, G. M., and Roberts, J. A.: Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology, 22: 1863-1873, 1995.
30. Janssen, H. L. A., Gerken, G., Carreño, V. et al.: Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. Hepatology, 30: 238-243, 1999.
31. Reichen, J., Bianchi, L., Frei, P. C. et al.: Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. J.Hepatol., 20: 168-174, 1994.
32. Cohard, M., Poynard, T., Mathurin, P. et al.: Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis. Hepatology, 20: 1390-1398, 1994.
33. Nair, P. V., Tong, M. J., Stevenson, D. et al.: Effects of short-term- high dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver, 5: 8-12, 1985.
34. Laskus, T., Slusarczyk, J., Cianciara, J. et al.: Exacerbation of chronic active hepatitis type B after short-term corticosteroid therapy resulting in fatal liver failure. Am J Gastroenterol., 85: 1414-1417, 1990.
35. Fattovich, G., Farci, P., Rugge, M. et al.: A randomized controlled trial lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology, 15: 584-589, 1992.
36. Hadziyannis, S., Bramou, T., Makris, A. et al.: Interferon alpha-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J.Hepatol., 11: 133-136, 1990.
37. Lampertico, P., Del Ninno, E., Manzin, A. et al.: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology, 26: 1621-1625, 1997.
38. Pastore, G., Santantonio, T., Milella, M. et al.: Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J.Hepatol., 14: 221-225, 1992.
39. Papatheodoridis, G. V., Manesis, E., and Hadziyannis, S. J.: The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J.Hepatol., 34: 306-313, 2001.
40. Chuang, W. L., Omata, M., Ehata, T. et al.: Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology, 104: 363-271, 1993.
41. Hoofnagle, J. H., Di Bisceglie, A. M., Waggoner, J. G. et al.: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology, 104: 1116-1121, 1993.
42. Nevens, F., Gouba, P., van Eyken, P. et al.: Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver, 13: 15-19, 1993.
43. Perrillo, R., Tamburro, C., Regenstein, F. et al.: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology, 109: 908-916, 1995.
44. Torre, D.. and. Tambini, R.: Interferon-a therapy for chronic hepatitis B in children: A meta- analysis. Clin.Infect.Dis., 23: 131-137, 1996.
45. Bortolotti, F., Jara, P., Barbera, C. et al.: Long term effect of alpha interferon in children with chronic hepatitis B. Gut, 46: 715-718, 2000.
46. Zeuzem, S., Feinman, S. V., Rasenack, J. et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N.Engl.J.Med., 343: 1666-1672, 7-12-2000.
47. Dienstag, J. L., Schiff, E. R., Wright, T. L. et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N.Engl.J.Med., 341: 1256-1263, 21-10-1999.
48. Lai, C. L., Chien, R. N., Leung, N. W. et al.: A one-year trial of lamivudine for chronic hepatitis B. N.Engl.J.Med., 339:61-68, 9-7-1998.
49. Liaw, Y. F., Lenng, N. W. Y., Chang, T. T. et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology, 119: 172-180, 2000.
50. Honkoop, P., Niesters, H. G., De Man, R. A. et al.: Lamivudine resistance in immunocompetent chronic hepatitis B - Incidence and patterns. J.Hepatol., 26: 1393-1395, 1997.
51. Hadziyannis, S. J., Papatheodoridis, G. V., Dimou, E. et al.: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 32: 847-851, 2000.
52. Lau, D. T. Y., Khokhar, F., Doo, E. et al.: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology, 32: 828-834, 2000.
53. Song, B. C., Suh, D. J., Lee, H. C. et al.: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology, 32: 803-806, 2000.
54. Ormseth, E. J., Holtzmuller, K. C., Goodman, Z. D. et al.: Hepatic decompensation associated with lamivudine: A case report and review of lamivudine-induced hepatotoxicity. Am.J.Gastroenterol., 96: 1619-1622, 2001.
55. Bruno, R., Sacchi, P., Filice, C. et al.: Acute liver failure during lamivudine treatment in a hepatitis B cirrhotic patient. Am.J.Gastroenterol., 96: 265-265, 2001.
56. Villeneuve, J. P., Condreay, L. D., Willems, B. et al.: Lamivudine treatment for decompensated cirrhosis resulting front chronic hepatitis B. Hepatology, 31: 207-210, 2000.
57. Yao, F. Y., and. Bass, N. M.: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J.Hepatol., 33: 301-307, 2000.
58. Tassopoulos, N. C., Volpes, R., Pastore, G. et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology, 29: 889-896, 1999.
59. Richman, D. D.: The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology, 32: 866-867, 2000.
60. De Man, R. A., Marcellin, P., Habal, F. et al.: A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology, 32: 413-417, 2000.
61. Trépo, C., Jezek, P., Atkinson, G. et al.: Famciclovir in chronic hepatitis B: results of a dose-finding study. J.Hepatol., 32: 1011-1018, 2000.
62. Perrillo, R., Schiff, E., Yoshida, E. et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32: 129-134, 2000.
63. Van Nunen, A. B., Baumann, M., Manns, M. P. et al.: Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver, 21: 207-212, 2001.
64. Schalm, S. W., Heathcote, J., Cianciara, J. et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 46: 562-568, 2000.
65. Barbaro, G., Zechini, F., Pellicelli, A. M. et al.: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J.Hepatol., 35: 406-411, 2001.
66. Serfaty, L., Thabut, D., Zoulim, F. et al.: Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study. Hepatology, 34: 573-577, 2001.
67. Lau, G. K. K. K., Tsiang, M., Hou, J. L. et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study. Hepatology, 32: 394-399, 2000.
68. De Man, R. A., Bartholomeusz, A. I., Niesters, H. G. et al.: The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J.Hepatol., 29: 669-675, 1998.
69. Mutimer, D., Pillay, D., Cook, P. et al.: Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J.Infect.Dis., 181: 713-716, 2000.
70. BAG/SKIV/SEVHEP: Empfehlungen zur Hepatitis-B-Impfung: Stand Dezember 1997. BAG Bulletin, 5 (Suppl. II): 4-5, 1998.
71. Zipp, F., Weil, J. G., and Einhäupl, K. M.: No increase in demyelinating diseases after hepatitis B vaccination. Nature Med., 5: 964-965, 1999.
72. Ascherio, A., Zhang, S. M., Hernán, M. A. et al.: Hepatitis B vaccination and the risk of multiple sclerosis. N.Engl.J.Med., 344: 327-332, 1-2-2001.
73. Empfehlungen zur Hepatitis-B-Impfung: Ergänzungen zum Supplement II vom Dez. 1997. BAG Bulletin, 36: 4-5, 1998.
74. Analyse der Wirtschaftlichkeit alternativer Hepatitis-B-Impfstrategien in der Schweiz. BAG Bulletin, 4: 3-6, 1998.